TEL AVIV, Israel – (COMMERCIAL THREAD) – Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that it will issue a press release on its financial results for the second quarter of 2021 on Wednesday, July 28, 2021 at 7:00 a.m. ET. Following the post, Teva will host a conference call and live webcast on the same day at 8:00 a.m. ET.
To participate, please dial the following numbers: United States 1-877-870-9135; Israel 1-809-213-985 or International +44 (0) 2071 928338; secret code : 9693275.
A live webcast of the call will be available on Teva’s website at: http://ir.tevapharm.com/.
After the call ends, a replay of the webcast will be available within 24 hours on Teva’s website or by calling the US at 1-866-331-1332; International +44 (0) 3333 009785; secret code : 9693275.
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) have been developing and producing drugs to improve people’s lives for over a century. We are a global leader in generic and specialty drugs with a portfolio of more than 3,500 products in almost all therapeutic areas. About 200 million people around the world take a Teva medicine every day and are served by one of the pharmaceutical industry’s largest and most complex supply chains. In addition to our established presence in generics, we have significant innovative research and operations activities supporting our growing portfolio of specialty and biopharmaceutical products. Learn more about www.tevapharm.com.
Caution Regarding Forward-Looking Statements
This document and the conference call may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, which are based on the current beliefs and expectations of management and are subject to substantial risks and uncertainties, known and unknown, which could cause our future results, performance or achievements to differ materially from those expressed or implied by such forward-looking statements. Important factors that could cause or contribute to such differences include risks related to: our ability to compete successfully in the market; our substantial debt; our business and operations in general; compliance, regulatory and litigation matters; other financial and economic risks; and other factors discussed in our Annual Report on Form 10-K for the year ended December 31, 2020 and our Quarterly Report on Form 10-Q for the first quarter of 2021, including in the sections entitled “Risk Factors “. Forward-looking statements speak only as of the date on which they are made, and we assume no obligation to update or revise any forward-looking statements or other information contained herein, whether as a result of new information, future events or otherwise. You are cautioned not to place undue reliance on these forward-looking statements.